Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
sitagliptin
|
| gptkbp:clinicalTrials |
yes
Phase III as monotherapy in combination with insulin in combination with metformin in combination with sulfonylureas in combination with thiazolidinediones |
| gptkbp:contraindication |
joint pain
skin reactions hypoglycemia pancreatitis kidney problems hypersensitivity to sitagliptin |
| gptkbp:date |
2006-10-16
|
| gptkbp:discontinued |
no
|
| gptkbp:diseaseResistance |
available
|
| gptkbp:dosageForm |
tablet
|
| gptkbp:drugInterdiction |
true
DPP-4 inhibitor |
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:healthcare |
stay hydrated
monitor blood sugar levels report severe allergic reactions |
| https://www.w3.org/2000/01/rdf-schema#label |
Januvia
|
| gptkbp:interactsWith |
insulin
sulfonylureas other diabetes medications thiazolidinediones |
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:offers |
varies by location
|
| gptkbp:patentExpiration |
2022-10-16
|
| gptkbp:patentType |
yes
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
headache
nausea diarrhea upper respiratory tract infection |
| gptkbp:skills |
100 mg
50 mg 25 mg |
| gptkbp:storage |
room temperature
away from moisture away from light |
| gptkbp:triggerType |
inhibits DPP-4 enzyme
|
| gptkbp:type |
yes
sitagliptin phosphate |
| gptkbp:usedFor |
type 2 diabetes
|